# IVXpress

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ivxpress

- Industry: Biotechnology
- Headquarters: Brentwood, US
- Website: www.ivxhealth.com
- Total disclosed funding: $166M
- Latest round: Series F (Sep 21, 2021)
- Investors on record: 6

## About

Based in Tennessee, US, and founded in 2013 by Doug Ghertner,  IVXpress, Inc., provides biologic injections and infusions for patients with chronic conditions. The company has approximately 50 infusion centers across 16 markets as of 2021. In September 2021, IVXpress, Inc. raised series F funding from Great Hill Partners.

IVXpress, Inc. works with adult and pediatric patients with chronic conditions such as multiple sclerosis, Crohn’s disease, rheumatoid arthritis, osteoporosis, pediatric and adult immunotherapy, vitamin and mineral deficiencies, and immune system disorders to provide hospital-based infusion and injection therapy through local centers.

As part of the 2021 funding, IVXpress, Inc. will accelerate its entry into new markets in 2022 and realize its vision of becoming the preferred destination for pharmaceutical care for patients with complex chronic conditions.

## Funding rounds

- Series F, Sep 21, 2021, $100M — Great Hill Partners, Linden Capital Partners, Nueterra Capital Management, McKesson Ventures, Health Velocity Capital
- Series E, Oct 13, 2020, $30M — Linden Capital Partners, Nueterra Capital Management, McKesson Ventures, Health Velocity Capital
- Series C, Jul 16, 2019, $23M — Nueterra Capital Management, McKesson Ventures, Health Velocity Capital, CrimsoNox Capital
- Series B, Oct 31, 2017, $14M — McKesson Ventures, Health Velocity Capital

## Investors

- McKesson Ventures (https://capitalatlas.ai/funds/mckesson-ventures) — Series B, Series C, Series E, Series F
- Health Velocity Capital (https://capitalatlas.ai/funds/health-velocity-capital) — Series B, Series C, Series E, Series F
- Nueterra Capital Management (https://capitalatlas.ai/funds/nueterra-capital-management) — Series C, Series E, Series F
- CrimsoNox Capital — Series C
- Linden Capital Partners (https://capitalatlas.ai/funds/linden-capital-partners) — Series E, Series F
- Great Hill Partners (https://capitalatlas.ai/funds/great-hill-partners) — Series F